Let's goooooooooooo!To the many haters who said this day would never come, it's here.
To the many haters who say this company is worthless, __ _____ ___.
PMN is moving foward. Slower than planned, and at great cost. But moving forward. By next year, PMN should be in a better position for financing Ph2 or striking a partnership deal.
The great hope... Phase 1b shows no ARIA E in AD patients relative to the control group and biomarkers show activity better than ACU193, leqembi, and all the rest.
Will the longs here stand strong and prevail? Will AD patients have a better alternative in four years?
Time will tell. HOPE remains. Which side will you be on? The haters, who bash this stock and its price, making future financing more costly? Or the believers, who see the science for what it is and endure the business storms, with the hope of coming away with the profit of ten lifetimes?
I'll be adding to my position. At this point, I'm getting a significantly lower price than those who just put in $20M. Does being down 50% hurt? Heck yes it hurts. But hope remains.